U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma
In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced